Cargando…

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

BACKGROUND: Quantify association between the glucagon-like peptide-1 receptor agonist liraglutide and risk of thyroid cancer (TC) compared to other antidiabetics. PATIENTS AND METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups of dipeptidyl peptidase-4 inhibitors or sul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Funch, Donnie, Mortimer, Kathleen, Ziyadeh, Najat J, D Seeger, John, Zhou, Li, Ng, Eva, Ross, Douglas, Major-Pedersen, Atheline, Bosch-Traberg, Heidrun, Gydesen, Helge, Dore, David D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203194/ https://www.ncbi.nlm.nih.gov/pubmed/34140791 http://dx.doi.org/10.2147/DMSO.S305496

Ejemplares similares

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
por: Funch, Donnie, et al.
Publicado: (2019)

Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies
por: Funch, Donnie, et al.
Publicado: (2017)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch, Donnie, et al.
Publicado: (2018)

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
por: Funch, D, et al.
Publicado: (2014)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data
por: Dore, David D, et al.
Publicado: (2014)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
por: Seino, Yutaka, et al.
Publicado: (2016)

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden
por: Lind, Marcus, et al.
Publicado: (2016)

Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial
por: Kveiborg, Britt, et al.
Publicado: (2007)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database
por: Ziyadeh, Najat J., et al.
Publicado: (2020)

Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database
por: Uzoigwe, Chioma, et al.
Publicado: (2022)

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
por: Zang, L., et al.
Publicado: (2016)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Does the Development of the Insurance Industry Promote the Purchase of Rural Commercial Health Insurance?
por: Li, Cong, et al.
Publicado: (2021)

Pricing in commercial dental insurance and provider markets
por: Nasseh, Kamyar, et al.
Publicado: (2020)

Pathways to reimagining commercial health insurance in India
por: Ashraf, Hasna, et al.
Publicado: (2022)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Treatment beliefs, health behaviors and their association with treatment outcome in type 2 diabetes
por: von Arx, Lill-Brith Wium, et al.
Publicado: (2016)

Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study
por: Kveiborg, Britt, et al.
Publicado: (2010)

HIV Testing among Outpatients with Medicaid and Commercial Insurance
por: Dietz, Patricia M., et al.
Publicado: (2015)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study
por: Falskov, Britt, et al.
Publicado: (2011)

The effect of chronic heart failure and type 2 diabetes on insulin-stimulated endothelial function is similar and additive
por: Falskov, Britt, et al.
Publicado: (2011)

Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US
por: Miloh, Tamir, et al.
Publicado: (2023)

Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice
por: Ji, Wenjun, et al.
Publicado: (2014)

Screening High School Students for Eating Disorders: Results of a National Initiative
por: Austin, S. Bryn, et al.
Publicado: (2008)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Presumed ocular histoplasmosis syndrome in a commercially insured population, United States
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

Care Among Migraine Patients in a Commercially Insured Population
por: Bonafede, Machaon, et al.
Publicado: (2020)

Influence of Commercial Insurance Purchase on the Health Status of Chinese Residents
por: Xu, Bao-Chang, et al.
Publicado: (2021)

Exposure to Abnormally Hot Temperature and the Demand for Commercial Health Insurance
por: Zhong, Qian, et al.
Publicado: (2022)

Healthcare use in commercially insured youth with mental health disorders
por: Hugunin, Julie, et al.
Publicado: (2022)

Influence of Internet Use on Commercial Health Insurance of Chinese Residents
por: Xu, Bao-Chang, et al.
Publicado: (2022)

Research on the Effect of Commercial Health Insurance Development on Economic Efficiency
por: Zhao, Tongpu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhita9nc7aqbsbmir9q7gh47m3